Technology Appraisal Committee Meeting Committee D

Minutes: Unconfirmed

Date and Time: Wednesday 28 June 2017, 10.00am – 17.10

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Professor Gary McVeigh (Chair) Present for all notes
2. Dr Lindsay Smith (Vice Chair) Present for all notes
3. Dr Aomesh Bhatt Present for all notes
4. Professor David Bowen Present for all notes
5. Dr Matthew Bradley Present for all notes
6. Dr Ian Davidson Present for all notes
7. Professor Simon Dixon Present for all notes
8. Mrs Susan Dutton Present for all notes
9. Professor Rachel Elliott Present for all notes
10. Mrs Gillian Ells Present for all notes
11. Professor Paula Ghaneh Present for all notes
12. Dr Rebecca Harmston Present for all notes
13. Dr Peter Hall Present for all notes
14. Dr David Meads Present for all notes
15. Mr Malcolm Oswald Present for all notes
16. Mr William Turner Present for all notes

In attendance:
Mariana Bacelar Evidence Review Group representative, Peninsula Technology Assessment Group, BMJ-TAG Present for notes 16 to 24
Dr Charlotte Benson Clinical expert, Consultant Medical Oncologist, nominated by GIST Support UK Present for notes 1 to 16
Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes
Dr Ramesh Bulusu Clinical expert, Consultant Oncologist, nominated by GIST Support UK Present for notes 1 to 16
Dianne Dobson Patient expert, nominated by Pancreatic Cancer UK Present for notes 28 to 26
James Dunham Evidence Review Group representative, Peninsula Technology Assessment Group (PenTAG) Present for notes 1 to 16
<table>
<thead>
<tr>
<th>Name</th>
<th>Role and Affiliation</th>
<th>Notes Present for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rui Duarte</td>
<td>Evidence Review Group representative, Liverpool Reviews and Implementation Group</td>
<td>28 to 36</td>
</tr>
<tr>
<td>Steve Edwards</td>
<td>Evidence Review Group representative, Peninsula Technology Assessment Group, BMJ-TAG</td>
<td>16 to 24</td>
</tr>
<tr>
<td>Christian Griffiths</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Tracey Jones-Hughes</td>
<td>Evidence Review Group representative, Peninsula Technology Assessment Group (PenTAG)</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Martin Hoyle</td>
<td>Evidence Review Group representative, Peninsula Technology Assessment Group (PenTAG)</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>All notes</td>
</tr>
<tr>
<td>Dr John Lear</td>
<td>Clinical expert, Consultant Dermatologist, nominated by Roche</td>
<td>16 to 24</td>
</tr>
<tr>
<td>Aimely Lee</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>16 to 27</td>
</tr>
<tr>
<td>Dr David Propper</td>
<td>Clinical expert, Consultant and Senior Lecturer in Medical Oncology, nominated by Celgene and NCRI-ACP-RCP-RCR</td>
<td>28 to 36</td>
</tr>
<tr>
<td>Dr Sheela Rao</td>
<td>Clinical expert, Consultant Medical Oncologist, nominated by Celgene</td>
<td>28 to 36</td>
</tr>
<tr>
<td>Vicky Rockingham</td>
<td>Patient expert, nominated by GIST Support UK</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Abitha Senthinathan</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Alex Sexton</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>1 to 16</td>
</tr>
<tr>
<td>Raisa Sidhu</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>16 to 27</td>
</tr>
</tbody>
</table>
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals ofregorafenib for treating advanced gastrointestinal stromal tumours, vismodegib for treating basal cell carcinoma and paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.

2. Apologies were received from Sumithra Maheswaran, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu.

Any other Business

3. None

Appraisal of regorafenib for treating advanced gastrointestinal stromal tumours
Part 1 – Open session

4. The Chair welcomed the invited experts: Dr Charlotte Benson, Dr Ramesh Bulusu James Dunham, Tracey Jones-Hughes, Martin Hoyle, Vicky Rockingham, and Emma Tennant to the meeting and they introduced themselves to the Committee.

5. The Chair welcomed company representatives from Bayer to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

   6.1. Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Rebecca Harmston, Dr Peter Hall, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Dr Lindsay Smith and Mr William Turner all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for treating advanced gastrointestinal stromal tumours.

7. The Chair asked all NICE Staff to declare any relevant interests.

   7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for treating advanced gastrointestinal stromal tumours.

8. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

   8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for treating advanced gastrointestinal stromal tumours.

9. The Chair introduced the lead team, Malcolm Oswald and Professor Simon Dixon, who gave presentations on the clinical effectiveness and cost effectiveness of regorafenib for treating advanced gastrointestinal stromal tumours.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session
13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of regorafenib for treating advanced gastrointestinal stromal tumours.

15. The Committee agreed to defer a decision until further economic analysis has been undertaken.

**Appraisal of vismodegib for treating basal cell carcinoma**

**Part 1 – Open session**

16. The Vice Chair welcomed the invited experts: Mariana Bacelar, Dr Steve Edwards, Dr John Lear and Dr Victoria Wakefield to the meeting and they introduced themselves to the Committee.

17. The Vice Chair welcomed company representatives from Roche Products to the meeting.

18. The Vice Chair asked all Committee members to declare any relevant interests

   18.1. Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ellis, Professor Paula Ghanem, Dr Rebecca Harmston, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Dr Lindsay Smith and Mr William Turner all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of vismodegib for treating basal cell carcinoma.

   18.2. Dr Peter Hall declared a non-personal non-specific financial interest as his university had received funding from the company for his participation in an advisory board.

      18.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

19. The Vice Chair asked all NICE Staff to declare any relevant interests.

   19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of vismodegib for treating basal cell carcinoma.

20. The Vice Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

   20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of vismodegib for treating basal cell carcinoma.
21. The Vice Chair introduced the lead team, Dr Matthew Bradley, Dr Peter Hall and Dr Rebecca Harmston, who gave presentations on the clinical effectiveness and cost effectiveness of vismodegib for treating basal cell carcinoma.

22. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Vice Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

24. The Vice Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

25. Discussion on confidential information continued. This information was supplied by the company.

26. The Committee continued to discuss the clinical and cost effectiveness of vismodegib for treating basal cell carcinoma.

26.1. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

Part 1 – Open session

28. The Chair welcomed the invited experts: Dianne Dobson, Rui Duarte, Dr David Proper, Dr Sheela Rao, and Angela Stainthorpe, to the meeting and they introduced themselves to the Committee.

29. The Chair welcomed company representatives from Celgene UK to the meeting.

30. The Chair asked all Committee members to declare any relevant interests

30.1. Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Rebecca Harmston, Professor Gary McVeigh, Dr David Meads, Mr Malcolm Oswald, Dr Lindsay Smith and Mr William Turner all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.

30.2. Dr Peter Hall declared a non-personal non-specific financial interest as his university has received funding from a comparator company for his participation in an advisory board.

30.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
30.3. Professor Simon Dixon declared a non-personal non-specific financial interest he is Director of a Health Economics Unit that has undertaken work for a comparator company on unrelated topics; he was not directly involved in the work and his university received payment for the work.

30.3.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.

31. The Chair asked all NICE Staff to declare any relevant interests.

31.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.

32. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

32.1. Dianne Dobson, Rui Duarte and Angela Stainthorpe declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.

32.2. Dr David Propper declared a personal non-specific financial interest as the company had supplied free of charge a drug for a trial for which he is chief investigator and had reimbursed him for attending an advisory board in 2016.

32.2.1. It was agreed that this declaration would not prevent Dr David Propper from participating in this section of the meeting

32.3. Dr Sheela Rao declared a personal non-specific financial interest as she had attended an advisory board for the company.

32.3.1. It was agreed that this declaration would not prevent Dr Sheela Rao from participating in this section of the meeting

33. The Chair gave presentations on the clinical effectiveness and cost effectiveness of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.

34. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

35. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

36. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

37. Discussion on confidential information continued. This information was supplied by the company.

38. The Committee continued to discuss the clinical and cost effectiveness of paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer.
38.1. The committee decision was based on consensus.

39. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

40. Wednesday 26 July, 10.00 – 17.00, at Mercure Manchester Piccadilly Hotel